13:49:32 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning DIGN 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-12 Extra Bolagsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning DIGN 0.00 SEK
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-25 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning DIGN 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-19 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning DIGN 0.00 SEK
2021-05-20 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2021-01-11 Extra Bolagsstämma 2021
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-26 Ordinarie utdelning DIGN 0.00 SEK
2020-06-25 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2020-02-10 Extra Bolagsstämma 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning DIGN 0.00 SEK
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-15 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-11-27 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-22 Kvartalsrapport 2018-Q1
2018-04-27 Ordinarie utdelning DIGN 0.00 SEK
2018-04-26 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-12-04 Extra Bolagsstämma 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-02 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-24 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-25 Kvartalsrapport 2016-Q1
2016-03-23 Ordinarie utdelning DIGN 0.00 SEK
2016-03-22 Årsstämma 2016
2016-02-24 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-05-19 Ordinarie utdelning DIGN 0.00 SEK
2015-02-24 Bokslutskommuniké 2014
2014-11-25 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-20 Kvartalsrapport 2014-Q1
2014-05-19 Ordinarie utdelning DIGN 0.00 SEK
2014-05-16 Årsstämma 2014
2014-03-04 Extra Bolagsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-11-28 Kvartalsrapport 2013-Q3
2013-08-28 Kvartalsrapport 2013-Q2
2013-08-28 Extra Bolagsstämma 2013
2013-05-22 Kvartalsrapport 2013-Q1
2013-05-22 Ordinarie utdelning DIGN 0.00 SEK
2013-05-21 Årsstämma 2013
2013-02-27 Bokslutskommuniké 2012
2012-11-28 Kvartalsrapport 2012-Q3
2012-10-30 Extra Bolagsstämma 2012
2012-09-28 Kapitalmarknadsdag 2012
2012-08-28 Kvartalsrapport 2012-Q2
2012-06-29 Årsstämma 2012
2012-05-28 Kvartalsrapport 2012-Q1
2012-02-27 Bokslutskommuniké 2011
2011-11-17 Kvartalsrapport 2011-Q3
2011-08-22 Kvartalsrapport 2011-Q2
2011-06-13 Ordinarie utdelning DIGN 0.00 SEK
2011-06-10 Årsstämma 2011
2011-05-30 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010
2010-11-18 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-06-21 Ordinarie utdelning DIGN 0.00 SEK
2010-05-18 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-12-21 Split DIGN 100:1
2009-11-18 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Dignitana är verksamt inom medicinteknik. Bolaget utvecklar, tillverkar och marknadsför medicinska hjälpmedel som primärt används som skalpkylningssystem vid cytostatikabehandling, vars syfte är att eliminera eller kraftigt reducera håravfall. Bolaget har global verksamhet främst inom Norden, Europa, Nordamerika och Asien. Dignitana grundades år 2007 och har sitt huvudkontor i Lund.
2021-11-03 07:55:00

New classification enables reimbursement to cancer centers providing DigniCap to chemotherapy patients

Dignitana (http://www.dignitana.com/), world leader in scalp cooling innovation, announces that the U.S. Centers for Medicare & Medicaid Services (CMS) has reassigned payment for scalp cooling for Medicare claims filed using CPT code 0662T. This treatment has been reassigned to New Technology APC 1520 with a National Average Payment of $1,850.50, effective January 1, 2022.

"This decision ensures that thousands of cancer patients will now have access to life-changing scalp cooling therapy that was previously financially out of reach," said William Cronin, Dignitana CEO. "It is a major milestone for Dignitana and for so many in the cancer treatment community who have worked tirelessly to make scalp cooling standard of care."

"When the American Medical Association announced the CPT codes for scalp cooling last fall, we initiated a plan to do our part to help the oncology community establish appropriate reimbursement. Medicare coverage is critical to our overall reimbursement efforts and will undoubtedly increase utilization with existing customers and drive demand for DigniCap at new facilities," Cronin added.

The CMS announcement comes after the agency previously published a National Coverage Determination (NCD) for Scalp Hypothermia During Chemotherapy to Prevent Hair Loss (scalp cooling) in June 2021 for APC 5732 (Level 2 Minor Procedures) with a proposed payment rate of $34.72. At that time Dignitana filed an appeal with the agency and initiated conversations, in conjunction with Paxman Scalp Coolers, to determine an appropriate payment level for Medicare coverage of scalp cooling.

An Ambulatory Payment Classification (APC) is the US government's method of paying facilities for outpatient services covered by Medicare. The new payment assignment enables facility reimbursement under the Medicare Hospital Outpatient Prospective Payment System (OPPS).

According to CMS (https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Fast-Facts) more than 62 million people rely on Medicare for their health insurance coverage. A 2018 study (https://pubmed.ncbi.nlm.nih.gov/29398469/) found that 14.8 percent of all Medicare beneficiaries have a cancer diagnosis. Additionally, in 2013 the American Cancer Society (https://www.fightcancer.org/sites/default/files/2013-Medicare-Chartbook-Online-Version.pdf) found that Medicare beneficiaries over the age of 65 account for 54 percent of all new cancer cases.

FDA cleared in 2015, The DigniCap Scalp Cooling System minimizes hair loss from chemotherapy in patients with solid tumors. In the United States the National Comprehensive Cancer Network® (NCCN) added scalp cooling to their annual guidelines as a Class 2A recommendation for patients with breast cancer in 2019 and ovarian cancer in 2020. These guidelines are widely recognized as the benchmark for oncology treatment coverage and reimbursement by clinicians and payors. DigniCap is available (https://dignicap.com/locations-us-list/) at over 250 locations in the United States.

Resources:

1. CMS Final Ruling Nov 2, 2022  - CMS-1753FC (page 232-233, scalp cooling)  (https://www.cms.gov/medicaremedicare-fee-service-paymenthospitaloutpatientpps/cms-1753-fc)

2. CMS Press Release Nov 2, 2022 "CMS OPPS/ASC Final Rule Increases Price Transparency, Patient Safety and Access to Quality Care" (https://www.cms.gov/newsroom/press-releases/cms-oppsasc-final-rule-increases-price-transparency-patient-safety-and-access-quality-care)

3. CMS Fact Sheet Nov 2, 2022 - CY 2022 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule (CMS-1753FC) (https://www.cms.gov/newsroom/fact-sheets/cy-2022-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center-0)

This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-11-2021 07:55 CET.